Eversept Partners, LP Cyma Bay Therapeutics, Inc. Transaction History

Eversept Partners, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$5.12 - $7.21 $431,595 - $607,774	-84,296 Closed	0 $0
Q2 2019 Nov 08, 2023	SELL	$6.05 - $13.66 $139,150 - $314,180	-23,000 Reduced 21.44%	84,296 $603,000
Q2 2019 Aug 13, 2019	SELL	$6.05 - $13.66 $139,150 - $314,180	-23,000 Reduced 21.44%	84,296 $604,000
Q1 2019 Nov 08, 2023	BUY	$8.16 - $13.42 $491,232 - $807,884	60,200 Added 127.82%	107,296 $1.42 Million
Q1 2019 May 14, 2019	BUY	$8.16 - $13.42 $491,232 - $807,884	60,200 Added 127.82%	107,296 $1.43 Million
Q4 2018 Nov 08, 2023	SELL	$6.54 - $11.74 $163,500 - $293,500	-25,000 Reduced 34.68%	47,096 $370,000
Q4 2018 Feb 13, 2019	SELL	$6.54 - $11.74 $163,500 - $293,500	-25,000 Reduced 34.68%	47,096 $371,000
Q3 2018 Nov 08, 2023	SELL	$10.88 - $14.52 $380,800 - $508,200	-35,000 Reduced 32.68%	72,096 $798,000
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $380,800 - $508,200	-35,000 Reduced 32.68%	72,096 $799,000
Q2 2018 Nov 08, 2023	BUY	$10.66 - $14.38 $1.14 Million - $1.54 Million	107,096 New	107,096 $1.44 Million
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $1.14 Million - $1.54 Million	107,096 New	107,096 $1.44 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.